Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at William Blair issued their Q4 2018 EPS estimates for shares of Sarepta Therapeutics in a research report issued to clients and investors on Friday. William Blair analyst T. Lugo forecasts that the biotechnology company will post earnings of ($0.39) per share for the quarter. William Blair currently has a “Outperform” rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Oppenheimer Holdings, Inc. set a $76.00 price objective on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 8th. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Credit Suisse Group set a $64.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Leerink Swann reaffirmed a “buy” rating and set a $60.00 target price (up from $52.00) on shares of Sarepta Therapeutics in a research note on Tuesday, July 18th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $50.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, July 20th. Nine research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $62.71.

ILLEGAL ACTIVITY WARNING: “Sarepta Therapeutics, Inc. Forecasted to Earn Q4 2018 Earnings of ($0.39) Per Share (SRPT)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/02/sarepta-therapeutics-inc-forecasted-to-earn-q4-2018-earnings-of-0-39-per-share-srpt.html.

Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at 45.36 on Monday. The company’s market capitalization is $2.92 billion. The stock’s 50 day moving average is $40.10 and its 200-day moving average is $34.92. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $63.03.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. During the same quarter last year, the business posted ($1.19) EPS. The business’s quarterly revenue was up 350000.0% compared to the same quarter last year.

In other Sarepta Therapeutics news, SVP Alexander Cumbo sold 5,918 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $242,638.00. Following the sale, the senior vice president now owns 22,793 shares in the company, valued at $934,513. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Douglas S. Ingram bought 47,058 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 27th. The stock was acquired at an average price of $42.50 per share, for a total transaction of $1,999,965.00. Following the purchase, the chief executive officer now owns 382,058 shares of the company’s stock, valued at $16,237,465. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 78,056 shares of company stock valued at $3,224,208. 9.60% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Prentiss Smith & Co. Inc. grew its holdings in shares of Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 3,166 shares during the last quarter. Ameritas Investment Partners Inc. bought a new stake in Sarepta Therapeutics during the 1st quarter valued at about $127,000. PNC Financial Services Group Inc. lifted its holdings in Sarepta Therapeutics by 150.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 2,800 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Sarepta Therapeutics by 116.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,474 shares in the last quarter. Finally, Edge Wealth Management LLC bought a new stake in Sarepta Therapeutics during the 2nd quarter valued at about $175,000. 65.41% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.